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Abstract- Background: Anxiety may negatively affect the course of coronary artery disease (CAD). The 
aim of this study was to assess which factors are associated with anxiety in young adults with CAD. A cohort 
of individuals with premature coronary artery disease was formed between 2004-2011, as the Tehran Heart 
Center's Premature Coronary Atherosclerosis Cohort (THC-PAC) study. Patients (men≤45-year-old, and 
women≤55-year-old) were visited between March 2013 and February 2014. All participants were examined, 
and their demographic, clinical, and laboratory data were collected. Then, all participants filled in the Beck 
Anxiety Inventory. Logistic regression models were used to identifying factors related to anxiety in both 
sexes. During the study, 708 patients (mean [SD] age: 45.3 [5.8] y, men:48.2%) were visited. Anxiety was 
present in 53.0% of participants (66.0% of women and 39.0% of men). The logistic regressions model 
showed that the associated factors for anxiety in men were opium usage (OR=1.89, 95% CI: 1.09-3.27), 
positive family history (OR=1.49, 95% CI:0.94-2.35), and creatinine serum level (OR=1.17, 95% CI:1.05-
1.303); and in women were major adverse cardiac events (MACE) during follow-up (OR=2.30, 95% CI:1.25-
4.23), hypertension (OR=1.71, 95% CI:1.07-2.73) and the duration of CAD (OR=0.99, 95% CI:0.98-1.00). In 
premature CAD patients, the determinants of anxiety seem to be different in each sex. Opium usage, positive 
family history of CAD, and creatinine serum levels in men, and MACE, hypertension, and duration of CAD 
in women appear the relevant factors in this regard. 
© 2016 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran, 2016;54(4):261-269. 
 




Development of coronary artery disease (CAD) in 
the early stages of life is commonly being referred to as 
premature CAD. This medical condition is challenging, 
particularly in the Middle East. (1) Furthermore, it has 
been reported that the prognosis of CAD is poorer in 
young than elderly patients (2). A common psychiatric 
symptom among CAD patients is anxiety, and it is 
estimated that around 20% of patients with coronary 
disease are anxious. (3) Emerging data have shown that 
anxiety is associated with increased risk of major 
adverse cardiac events and mortality (4), and is a 
predictor of poor clinical outcome in CAD patients. (5) 
The association between anxiety and sudden cardiac 
death has been shown in several previous studies and in 
a 32-year follow-up of 2280 community-dwelling men, 
in which study those individuals with high anxiety had a 
4.5-fold increased risk of sudden cardiac death. (6) The 
association anxiety and CAD has two directions, as 
CAD development may also result in anxiety. 
Anxiety and premature CAD 
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Unlike depression which has amply been studied in 
CAD patients, the role of anxiety in CAD development 
is not well-understood (7). Anxiety is commonly under-
recognized or untreated in CAD patients. In a study on 
admitted patients with myocardial infarction (MI), it has 
been shown that health care providers had failed to 
diagnose anxiety in about 50% of patients (8). Early 
detection of anxiety in premature CAD patients may 
help to decrease CAD progression by appropriate 
psychiatric interventions. This study, which is a sub-
study of Tehran Heart Center's Premature Coronary 
Atherosclerosis Cohort (THC-PAC) study (9), was 
designed to identify putative factors associated with 
anxiety and CAD in young adults. 
 
Materials and Methods 
 
Design and subject 
The current study is a cross-sectional study within 
the THC-PAC study. The methods of THC-PAC study 
have been described elsewhere (9). 
THC-PAC study comprises a cohort of CAD 
patients, who are residents of Tehran or its suburbs, 
men≤ 45 years old and women≤ 55 years old, with 
nearly the same sex distribution. They underwent 
coronary angiography between June 2004 and July 2011 
and had angiographically documented CAD. Follow-up 
extended from cohort entry to the present and was 
performed from August 2012 via either clinical visits or 
telephone calls, at least once a year. 
The current study was done between March 2013 
and February 2014. The participants were examined at 
the premature CAD clinic of Tehran Heart Center, and 
all of them signed the relevant, informed consent and 
filled in the Beck Anxiety Inventory. 
 
Measures 
Coronary artery disease was defined as at least ≥ 
50% luminal stenosis in individual epicardial vessels. 
Demographic, clinical and laboratory data were 
collected at the time of angiography and were 
considered as the baseline data. Recent clinical and 
laboratory data were re-collected by a trained physician 
at clinical visits.  
Anxiety was assessed by Beck Anxiety Inventory 
(BAI) at the clinical visit. BAI is designed for 
individuals with an age range of 17–80-year-old. This 
inventory is a self-report questionnaire and consists of 
twenty-one multiple-choice questions. BAI is one of the 
most commonly used inventories for measuring the 
presence and severity of anxiety. Participants rate the 
severity of their anxiety symptoms during the last 2 
weeks on a four-point scale ranging from zero to three 
and finally it is summed to a final single score. The final 
sum scores ranging from zero to 7 indicate minimally, or 
no anxiety, from 8 to 15 indicate mild, from 16 to 25 
indicate moderate, and 26 to 63 indicate severe anxiety, 
respectively (10). In this study, we considered the sum 
score ≥ 8 as the cut-off point for defining an anxiety 
problem. Baseline anxiety status was not assessed at the 
time of angiography.  
Body mass index (BMI) was calculated by dividing 
weight (in kilogram) by height (in square meters). 
According to the American Heart Association definition, 
BMI values less than 18.5 kg/m², from 18.5 kg/m² to 
24.9 kg/m², from 25.0 to 29.9 kg/m², and ≥ 30.0 kg/m², 
was considered as underweight, normal, overweight, and 
obese, respectively (11). 
In this study, major adverse cardiac events (MACE) 
were defined as new MI; new coronary vessel 
involvement; stroke; undergoing percutaneous coronary 
intervention (PCI); or undergoing coronary artery 
bypass surgery (CABG) after the initial diagnosis of 
CAD. Revascularizations (PCIs or CABGs) which were 
done in the early stages of the first diagnosis of CAD (as 
the early treatment strategy) were not considered as 
MACE during follow-up. 
 
Statistical analysis 
Categorical variables were expressed as the 
frequency with percentage, and chi-squared test was 
used for comparison between anxiety and non-anxiety 
groups or between the sexes. Continuous variables were 
presented as means and standard deviation (SD), and 
Student’s t-test was used for comparing anxiety and 
non-anxiety groups and also between the sexes. We used 
backward logistic regression model, with probabilities of 
removal and entry as 0.1 and 0.05, respectively, to find 
factors associated with anxiety in all patients and in each 
sex group. All variables with P-values less than 0.2 in 
univariate analyzes were a candidate to enter the 
multivariable model. Effects of covariates on anxiety 
were reported as an odds ratio (OR) with 95% 
confidence interval (CI) derived from the model. Model 
calibration was assessed through Hosmer & Lemeshow 
goodness of fit test. Model discrimination power was 
evaluated using c-statistic which is equal to the area 
under the Receiver Operating Characteristic (ROC) 
curve. All statistical analyzes were done using IBM 
SPSS for Windows version 22 (Armonk, NY: IBM 
Corp.). 
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Results 
 
During the study, 708 young patients with premature 
CAD, 367 men (48.2%) and 403 women (51.8%) with a 
mean age of 45.32±5.78 years were visited. The mean 
duration of follow-up was 55.77±38.67 months. Table 1 
shows the characteristics of these patients. 
 
 
Table 1. Patients Characteristics* 






Age (y) 45.32±5.78 41.10±3.38 49.25±4.66 <0.001 
Risk Factors     
Positive Family History 318 (44.9) 146 (42.8) 172 (46.9) 0.279 
Hypertension 340 (48.0) 103 (30.2) 237 (46.9) <0.001 
Hyperlipidemia 510 (72.2) 239 (70.1) 271 (73.8) 0.266 
Diabetes Mellitus 241 (34.0) 59 (17.3) 182 (49.6) <0.001 
Cigarette Smoking 243 (34.3) 219 (64.2) 24 (6.5) <0.001 
Opium Usage 72 (10.2) 70 (20.5) 2 (0.5) <0.001 
No Risk Factor 27 (3.8) 15 (4.4) 12 (3.3) 0.433 
BMI (kg/m2) 29.10±4.70 28.11±3.91 30.03±5.16 <0.001 
BMI Categories    <0.001 
Underweight  2 (0.3) 1 (0.3) 1 (0.3)  
Normal 124 (17.5) 69 (20.2) 55 (15.0)  
Overweight 317 (44.8) 171 (50.1) 146 (39.8)  
Obese 265 (37.4) 100 (29.3) 165 (45.0)  
Creatinine (mg/dl) 0.94±0.23 1.03±0.21 0.86±0.21 <0.001 
EF (%) 52.85±9.96 51.21±10.14 54.36±9.55 <0.001 
Abdominal Circumference (cm) 98.69±11.74 98.05±9.26 99.29±13.65 0.159 
MI at Baseline 310 (43.8) 206 (60.4) 104 (28.3) <0.001 
No. of Involved Vessels    0.007 
SVD 324 (45.8) 136 (39.9) 188 (51.2)  
2VD 188 (26.6) 96 (28.2) 92 (25.1)  
3VD 196 (27.7) 109 (32.0) 87 (23.7)  
Left Main Coronary Involvement 10 (1.4) 4 (1.2) 6 (1.6) 0.603 
Initial Treatment    0.142 
Medical Treatment 218 (30.8) 93 (27.3) 125 (34.1)  
PCI 321 (45.3) 161 (47.2) 160 (43.6)  
CABG 169 (23.9) 87 (25.5) 82 (22.3)  
MACE 142 (20.1) 63 (18.5) 79 (21.5) 0.311 
Duration of F/U (mo) 58.01±21.92 58.00±20.97 58.02±22.79 0.880 
* Data are presented as mean±SD or n (%) 
BMI, Body mass index; EF, Ejection fraction; MI, Myocardial infarction; SVD, Single-vessel disease; 2VD, Two-
vessel disease; 3VD, Three-vessel disease; PCI, Percutaneous coronary intervention; CABG, Coronary artery bypass 
grafting; MACE; Major adverse cardiac events; F/U, Follow-up 
 
 
Based on BAI results, 375 (53.0%) patients had anxiety 
(mild anxiety: 203 [28.7%], moderate anxiety: 112 
[15.8%], and severe anxiety: 60 [8.5%]). At first, the 
univariable analysis was done to find out which factors 
are associated with anxiety in our premature CAD 
patients. Table 2 depicts the results of this analysis.  
Patients with anxiety were older, and the frequency of 
anxiety was higher in women than men. Hypertension 
and smoking were more prevalent in the anxiety group, 
and BMI was also higher in this group. Patients with a 
history of MI at the baseline and those with MACE 
during follow-up were more frequently anxious than 
those without. 
A multivariable model was used to find out the possible 
associated factors with anxiety in premature CAD 
patients. Table 3 shows the results of that model. Sex, 
hypertension, and MACE remained still associated with 
anxiety.  
Since sex was a clear determinant of anxiety (OR: 2.7, 
95%CI: 1.96-3.75; P <0.0001), we stratified the groups 
by sex and re-performed analyzes.  
The characteristics of the male premature CAD patients, 
based on their anxiety status, has been depicted in Table 
4. As this table shows, 39.0% of the male patients had 
anxiety. In univariable analysis, except for the patients 
with elevated serum levels of creatinine who had a high 
prevalence of anxiety, the other variables were not 
significantly associated with anxiety in men.  
However, as depicted in Table 5, the multivariable 
model showed that opium usage (OR=1.90, 95%CI: 
Anxiety and premature CAD 
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1.094-3.275), positive family history (OR=1.49, 95%CI: 
0.941-2.346), and creatinine serum level (OR=1.17, 
95%CI: 1.046-1.303) were associated with anxiety in 
male patients with premature CAD. 
In the 367 female patients, 242 (66.0%) had anxiety. 
The patients’ characteristics and the univariable analysis 
based on the anxiety status in women are depicted in 
Table 6. As shown in this table, the prevalences of 
hypertension and history of MACE were higher in 
female patients with anxiety than those without, and 
they were more obese than non-anxiety patients.  
Table 7 shows the results of the multivariable models in 
female premature CAD patients. This analysis showed 
that history of MACE (OR=2.30, 95%CI: 1.247-4.226), 
hypertension (OR=1.71, 95%CI: 1.069-2.728) and the 
duration of CAD (OR=0.99, 95%CI: 0.979-1.000) were 
associated with anxiety in women.  
 
Table 2. Demographic, clinical, and paraclinical comparison between all patients with and 








95% CI for OR 
Lower Upper 
Age (y) 44.24±5.63 46.29±5.74 <0.001 1.065 1.037 1.094 
Sex   <0.001 3.028 2.228 4.114 
Male 208 (62.5) 133 (35.5)     
Female 125 (37.5) 242 (64.5)     
Risk Factors       
Positive Family History 141 (42.3) 177 (47.2) 0.195 1.217 0.904 1.639 
Hypertension 131 (39.4) 209 (55.7) <0.001 1.941 1.439 2.620 
Hyperlipidemia 238 (71.5) 272 (72.5) 0.753 1.054 0.759 1.464 
Diabetes Mellitus 102 (30.6) 139 (37.1) 0.071 1.334 0.975 1.825 
Cigarette Smoking 140 (42.0) 103 (27.5) <0.001 0.522 0.381 0.715 
Opium Usage 36 (10.8) 36 (9.6) 0.595 0.876 0.538 1.427 
No Risk Factor 14 (4.2) 13 (3.5) 0.609 1.222 0.566 2.639 
BMI (kg/m2) 28.46±4.64 29.67±4.68 <0.001 1.059 1.024 1.094 
BMI Categories   0.003    
Underweight  2 (0.6) 0     
Normal 70 (21.0) 54 (14.4)     
Overweight 157 (47.1) 160 (42.7)     
Obese 104 (31.2) 161 (42.9)     
Creatinine (mg/dl) 0.95±0.21 0.93±0.24 0.453 0.777 0.402 1.501 
EF (%) 52.65±9.97 53.03±9.95 0.618 1.004 0.989 1.019 
Abdominal 
Circumference (cm) 97.93±10.65 99.37±12.60 0.109 1.011 0.998 1.024 
MI at Baseline 163 (48.9) 147 (39.2) 0.009 0.672 0.499 0.906 
No. of Involved Vessels   0.041    
SVD 136 (40.8) 188 (50.1)  Ref   
2VD 94 (28.2) 94 (25.1)  0.723 0.504 1.038 
3VD 103 (30.9) 93 (24.8)  0.653 0.457 .933 
Left Main Coronary 
Involvement 6 (1.8) 4 (1.1) 0.408 0.588 0.164 2.100 
Initial Treatment   0.453    
Medical Treatment 97 (29.1) 121 (32.2)  Ref   
PCI 150 (45.0) 171 (45.6)  0.914 0.647 1.291 
CABG 86 (25.8) 83 (22.1)  0.774 0.517 1.158 
MACE 51 (15.3) 91 (24.3) 0.003 1.772 1.211 2.592 
Duration of F/U 59.00±22.83 57.13±21.07 0.344 0.996 0.989 1.003 
* Data are presented as mean±SD or n (%) 
BMI, Body mass index; EF, Ejection fraction; MI, Myocardial infarction; SVD, Single-vessel disease; 2VD, Two-vessel 
disease; 3VD, Three-vessel disease; PCI, Percutaneous coronary intervention; CABG, Coronary artery bypass grafting; 
MACE, Major cardiac adverse events; F/U, Follow-up 
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Female 2.709 1.957 3.749 <0.001 
HTN 1.393 1.006 1.928 0.046 
MACE  1.730 1.165 2.569 0.007 
Hosmer-Lemeshow test, P=0.426; The area under the ROC curve: 0.670 (95% CI: 0.630-0.710), P<0.001 
CAD, Coronary artery disease; HTN, Hypertension; MACE, Major adverse cardiac events 
 
 
Table 4. Demographic, clinical, and paraclinical comparison between male patients 
with and without anxiety (n=341)* 
 Non-Anxiety (n=208) 
Anxiety 
(n=133) P-Value OR 
95% CI for OR 
Lower Upper 
Age (y) 41.22±3.22 40.90±3.60 0.395 0.973 0.912 1.037 
Risk Factors       
Positive Family 
History 82 (39.4) 64 (48.1) 0.113 1.425 0.918 2.212 
Hypertension 61 (29.3) 42 (31.6) 0.659 1.112 0.694 1.783 
Hyperlipidemia 146 (70.2) 93 (69.9) 0.958 0.987 0.614 1.588 
Diabetes Mellitus 35 (16.8) 24 (18.0) 0.772 1.088 0.614 1.928 
Cigarette Smoking 130 (62.5) 89 (66.9) 0.407 1.412 0.768 1.918 
Opium Usage 36 (17.3) 34 (25.6) 0.066 1.641 0.966 2.788 
No Risk Factor 12 (5.8) 3 (2.3) 0.123 2.653 0.734 9.584 
BMI (kg/m2) 27.95±3.91 28.37±3.90 0.337 1.028 0.972 1.087 
BMI Categories   0.653    
Underweight  1 (0.5) 0     
Normal 44 (21.2) 25 (18.8)     
Overweight 106 (51.0) 65 (48.9)     
Obese 57 (27.4) 43 (32.3)     
Creatinine (mg/dl) 1.00±0.19 1.07±0.22 0.009 4.407 1.493 13.007 
EF (%) 51.08±10.15 51.43±10.16 0.759 1.004 0.981 1.026 
Abdominal 
Circumference (cm) 97.73±9.27 98.53±9.25 0.438 1.009 0.986 1.034 
MI at Baseline 128 (61.5) 78 (58.6) 0.594 0.886 0.569 1.382 
No. of Involved 
Vessels   0.373    
SVD 77 (37.0) 59 (44.4)  Ref   
2VD 60 (28.8) 36 (27.1)  0.783 0.459 1.336 
3VD 71 (34.1) 38 (28.6)  0.698 0.415 1.175 
Left Main Coronary 
Involvement 3 (1.4) 1 (0.8) 0.564 0.518 0.053 5.029 
Initial Treatment   0.963    
Medical Treatment 57 (27.4) 36 (27.1)  Ref   
PCI 99 (47.6) 62 (46.6)  0.992 0.587 1.675 
CABG 52 (25.0) 35 (26.3)  1.066 0.586 1.938 
CAD Duration (mo) 57.96±21.75 58.06±19.78 0.849 1.000 0.990 1.011 
MACE 34 (16.3) 29 (21.8) 0.205 1.427 0.822 2.478 
* Data are presented as mean±SD or n (%) 
BMI, Body mass index; EF, Ejection fraction; MI, Myocardial infarction; SVD, Single-vessel disease; 2VD, Two-
vessel disease; 3VD, Three-vessel disease; PCI, Percutaneous coronary intervention; CABG, Coronary artery 
bypass grafting; CAD, Coronary artery disease; MACE, Major cardiac adverse events 
 
 
Anxiety and premature CAD 
 
266    Acta Medica Iranica, Vol. 54, No. 4 (2016)  




Interval P-Value Lower Upper 
Positive Family History 1.486 0.941 2.346 0.089 
Opium Usage 1.893 1.094 3.275 0.023 
Creatinine (per 0.1 mg/dl increase) 1.167 1.046 1.303 0.006 
Hosmer-Lemeshow test, P=0.326; The area under the ROC curve: 0.606 (95% CI: 0.543-0.670), 
P=0.001 
CAD, Coronary artery disease 
 
Table 6. Demographic, clinical, and paraclinical comparison between female patients with and 
without anxiety (n=367)* 
 Non-Anxiety (n=125) 
Anxiety 
(n=242) P-Value OR 
95% CI for OR 
Lower Upper 
Age (y) 49.27±5.17 49.24±4.39 0.956 0.999 0.953 1.046 
Risk Factors       
Positive Family History 59 (47.2) 113 (46.78) 0.927 0.980 0.636 1.510 
Hypertension 70 (56.0) 167 (69.0) 0.014 1.750 1.120 2.733 
Hyperlipidemia 92 (73.6) 179 (74.4) 0.940 1.019 0.624 1.664 
Diabetes Mellitus 67 (53.6) 115 (47.5) 0.270 0.784 0.509 1.208 
Cigarette Smoking 10 (8.0) 14 (5.8) 0.416 0.706 0.304 1.639 
Opium Usage 0 2 (0.8) 0.308    
No Risk Factor 2 (1.6) 10 (4.1) 0.196 0.377 0.081 1.749 
BMI (kg/m2) 29.32±5.56 30.39±4.92 0.059 1.043 0.998 1.090 
BMI Categories   0.036    
Underweight  1 (0.8) 0     
Normal 26 (20.8) 29 (12.0)     
Overweight 51 (40.8) 95 (39.3)     
Obese 47 (37.6) 118 (48.8)     
Creatinine (mg/dl) 0.85±0.21 0.86±0.21 0.706 1.219 0.437 3.397 
EF (%) 55.31±9.11 53.87±9.76 0.187 0.984 0.961 1.008 
Abdominal 
Circumference (cm) 98.26±12.65 99.84±14.14 0.303 1.009 0.992 1.026 
MI at Baseline 35 (28.0) 69 (28.5) 0.918 1.026 0.636 1.657 
No. of Involved Vessels   0.541    
SVD 59 (47.2) 129 (53.3)  Ref   
2VD 34 (27.2) 58 (24.0)  0.780 0.462 1.317 
3VD 32 (25.6) 55 (22.7)  0.786 0.461 1.340 
Left Main Coronary 
Involvement 3 (2.4) 3 (1.2) 0.406 0.510 0.102 2.567 
Initial Treatment   0.276    
Medical Treatment 40 (32.0) 85 (35.1)  Ref   
PCI 51 (40.8) 109 (45.5)  1.006 0.609 1.661 
CABG 34 (27.2) 48 (19.8)  0.664 0.373 1.184 
CAD Duration (mo) 60.73±24.52 56.62±21.76 0.147 0.992 0.983 1.002 
MACE 17 (13.6) 62 (25.6) 0.008 2.188 1.216 3.937 
* Data are presented as mean±SD or n (%) 
BMI, Body mass index; EF, Ejection fraction; MI, Myocardial infarction; SVD, Single-vessel disease; 2VD, Two-vessel disease; 
3VD, Three-vessel disease; PCI, Percutaneous coronary intervention; CABG, Coronary artery bypass grafting; CAD, Coronary 
artery disease; MACE, Major cardiac adverse events
 
Table 7. Associated factors with anxiety in female patients with premature CAD 
 Odds Ratio 95% Confidence Interval P-Value 
  Lower Upper  
HTN 1.708 1.069 2.728 0.025 
MACE 2.296 1.247 4.226 0.008 
Duration of CAD 0.989 0.979 1.000 0.041 
Hosmer-Lemeshow test, P=0.270; The area under the ROC curve: 0.636 (95% CI: 0.577-0.696), P<0.001 
CAD, Coronary artery disease; HTN, Hypertension; MACE, Major adverse cardiac events 
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In our study, 53.0% of premature CAD patients were 
anxious with a standardized anxiety scaling instrument. 
Previous studies found anxiety in around 20% of CAD 
patients (3). This may serve to show that young adults 
with CAD are more susceptible to anxiety than older 
patients. Cardiac events may result in anxiety due to 
concerns about death or worsening the medical 
condition, or due to sympathetic discharges associated 
with myocardial ischemia, arrhythmias, and heart 
failure. Medications (such as sympathomimetics, and 
bronchodilators) administered to the cardiac patients, 
may also cause anxiety. Meanwhile, anxiety may 
exacerbate cardiac problems, and emotional stress may 
have significant adverse effects on the heart. Emotional 
stress may result in left ventricular contractile 
dysfunction, myocardial ischemia, or arrhythmia (12). 
Furthermore, anxiety can decrease adherence to medical 
recommendations (13), and it may increase the use of 
medical cares (14). 
We found that young adult women with CAD were 
more likely to be anxious than men. It is widely 
documented that women more often develop anxiety 
than men throughout the lifespan (15). The National 
Comorbidity Survey (conducted between 1990 and 
1992) showed that lifetime prevalence rates for anxiety 
were 19.2% in men and 30.5% in women (16). The 
prevalence of anxiety in either sex is even higher in 
CAD patients. A study by Todaro et al., on 150 patients 
with CAD showed 58.3% of women and 25.5% of men 
had anxiety (17). In our study, 66.0% of female and 
39.0% of the male patients had anxiety which was 
considerably higher than in previously done studies on 
CAD patients. Recent studies have shown that the onset, 
presentation, the clinical course, and the response to 
treatment of women with anxiety are different from 
men. It appears that the female reproductive hormone 
cycle plays a significant role in this regard (18). 
In the male patients, opium usage showed the 
greatest association with anxiety (OR=1.90). This 
substance is among the most commonly used drugs in 
the Middle East, including Iran. Previous studies have 
showed that opioid dependence is associated with 
anxiety (19). There are some studies which reported an 
increased prevalence of anxiety, as the most common 
psychiatric findings in substance abusers (20). However, 
in a study on 150 opium addicts in Shiraz, Iran, it was 
found that the most frequent symptom among opium 
abusers was depression rather than anxiety (21). There is 
also a report of an augmentation of consuming of 
substances (drugs and alcohol), with a prevalence of 
24% in patients with severe anxiety (20). 
Positive family history of CAD was the other factor 
associated with anxiety in the male patients. There was a 
positive family history of CAD in our 48.1% of anxious 
and 39.4% of non-anxious male patients. This may 
implicate the role of genetic factors for both anxiety and 
premature CAD, which needs further investigations. 
Patients with a positive family history of CAD may be 
concerned about early death as witnessed by their 
parents or first-degree relatives, which may lead to 
anxiety. 
Among the factors associated with anxiety in the 
male patients, every 0.1 mg/dl increase in serum level of 
creatinine led to a 1.17-fold increase in the odds of 
anxiety. Anxiety has been shown to be associated with 
both renal failure (22) and CAD (23). Furthermore, 
anxiety is considered as a robust indicator of suicidal 
ideation in renal patients who are on maintenance 
hemodialysis (24). CAD patients with renal problems 
have a more severe condition, and it is, therefore, 
plausible they become anxious.  
In women, history of MACE (MI, new coronary 
involvement, stroke, or revascularization) during follow-
up, showed the strongest association with anxiety 
(OR=2.30). Among our 79 female patients with a history 
of MACE, anxiety was present in 62 (78.5%) of them 
while in 288 female patients without a history of 
MACE, 186 (62.5%) were anxious. In a two-year 
follow-up study of 804 patients with stable CAD, it has 
been reported that anxiety could predict MACE (cardiac 
death, myocardial infarction, cardiac arrest, or 
nonelective revascularization) in the 2 years after 
baseline (OR=1.67; 95% CI: 1.18-2.37), with no sex 
difference. (25) In contrast, in our study, developing 
cardiac events seems to be the most stressful issue in 
women with premature CAD. 
Hypertension was the other associated factor with 
anxiety in women (OR=1.71), and it was more prevalent 
among our anxious than non-anxious women (69.0% vs. 
56%). Hypertension is a well-known traditional risk 
factor for CAD, and there is an increased risk of 
hypertension in patients with anxiety. In 2005, a 
population-based study on 1,000,000 random subjects 
from The National Health Research Institute database 
showed that the prevalence of hypertension in patients 
with anxiety was higher than that in the general 
population (37.9% vs. 12.4%; OR=2.61, 95% CI: 2.52-
2.70) (26). In the human body, anxiety is mediated 
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through the hypothalamic-pituitary-adrenal axis and 
catecholamines. By changes in circulating 
catecholamine levels, anxiety can adversely affect 
autonomic and hormonal homeostasis which may result 
in hypertension, inflammation, metabolic disorders, and 
endothelial dysfunction, which can finally contribute to 
the development and progression of CAD (27). In our 
study, women were frequently hypertensive than men 
(46.9 vs. 30.2, P<0.001). Since women in our study 
were about 8 years older than men, it may affect the 
prevalence of hypertension to be more prevalent in 
women. 
In the female patients, duration of the CAD showed a 
negative association with anxiety, as every year after 
CAD development had 1.01 fold decrease in odds of 
anxiety. It shows that as the duration of the CAD 
extends, patients can cope with the new medical 
condition, more appropriately. 
The current study suffers from some limitations. The 
most important one is the absence of baseline anxiety 
status. Another limitation is that other psychological 
factors, particularly depression, may interact with 
anxiety and may influence the detected associations, 
whereas determining these interactions was beyond what 
the current study design permitted. Concerning the 
generalizability of the results, since our participants 
were young adult CAD patients, the findings of the 
current study may not be generalizable to older patients. 
Also, we included patients with stable angina, and the 
findings may not be generalizable to patients with the 
acute coronary syndrome. Recruiting a considerably 
large sample of participants with premature CAD, and 
including a large proportion of women, contrary to many 
previous studies, are the strengths of this study. 
There are strong associations between coronary 
disease in the young and anxiety. To prevent mortality 
and unfavorable outcomes in terms of mental and 
physical health, both cardiologists and psychiatrists 
should be aware of these associations, particularly in 
young adults. Our study showed that the determinants of 
anxiety appear to be different in the sexes. While opium 
usage, positive family history of CAD, and creatinine 
serum levels are the factors associated with anxiety in 
men with premature CAD; history of MACE, 
hypertension, and duration of CAD are the relevant 
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